Caris Life Sciences, Inc. (CAI) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 5, 2026, Caris Life Sciences, Inc. (CAI) trades at a price-to-earnings ratio of -6.2x, with a stock price of $19.86 and trailing twelve-month earnings per share of $-0.32.
The current P/E is 124% below its 5-year average of 25.4x. Over the past five years, CAI's P/E has ranged from a low of 9.5x to a high of 41.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.2x, CAI trades at a 127% discount to its sector peers. The sector includes 226 companies with P/E ratios ranging from 0.0x to 194.6x.
Relative to the broader market, CAI trades at a notable discount to the S&P 500 median P/E of 26.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CAI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Diagnostics and Omics Tools peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $3B | 44.2Lowest | -Best | +165%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $30.25 | $0.73 | 41.3x | +63% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $26.72 | $2.82 | 9.5x | -63% |
Average P/E for displayed period: 25.4x
See CAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAI Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CAI vs LLY
See how CAI stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is CAI stock overvalued or undervalued?
CAI trades at -6.2x P/E, below its 5-year average of 25.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CAI's valuation compare to peers?
Caris Life Sciences, Inc. P/E of -6.2x compares to sector median of 23.2x. The discount suggests lower growth expectations or higher risk.
What is CAI's PEG ratio?
CAI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.